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Abstract
The use of doxorubicin (DOXO) as a chemotherapeutic drug has been hampered by cardiotoxicity leading to cardiomyopathy and heart failure. Folic
acid (FA) is a modulator of endothelial nitric oxide (NO) synthase (eNOS), which in turn is an important player in diseases associated with NO insuf-
ficiency or NOS dysregulation, such as pressure overload and myocardial infarction. However, the role of FA in DOXO-induced cardiomyopathy is
poorly understood. The aim of this study was to test the hypothesis that FA prevents DOXO-induced cardiomyopathy by modulating eNOS and
mitochondrial structure and function. Male C57BL/6 mice were randomized to a single dose of DOXO (20 mg/kg intraperitoneal) or sham. FA sup-
plementation (10 mg/day per oral) was started 7 days before DOXO injection and continued thereafter. DOXO resulted in 70% mortality after
10 days, with the surviving mice demonstrating a 30% reduction in stroke volume compared with sham groups. Pre-treatment with FA reduced
mortality to 45% and improved stroke volume (both P < 0.05 versus DOXO). These effects of FA were underlain by blunting of DOXO-induced car-
diomyocyte atrophy, apoptosis, interstitial fibrosis and impairment of mitochondrial function. Mechanistically, pre-treatment with FA prevented
DOXO-induced increases in superoxide anion production by reducing the eNOS monomer:dimer ratio and eNOS S-glutathionylation, and attenuated
DOXO-induced decreases in superoxide dismutase, eNOS phosphorylation and NO production. Enhancing eNOS function by restoring its coupling
and subsequently reducing oxidative stress with FA may be a novel therapeutic approach to attenuate DOXO-induced cardiomyopathy.
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Introduction
The use of DOXO, a member of the anthracycline family, as an effec-
tive broad spectrum chemotherapeutic drug has been hampered by
its dose-dependent cardiotoxicity, which leads to cardiomyopathy and
heart failure [1]. Approximately 5% of patients who receive 400–
450 mg/m2 DOXO develop heart failure that may not be recognized
for years [2]. The mechanisms underlying DOXO-induced
cardiomyopathy are not completely understood, but may include
direct effects on DNA, alteration of mitochondrial metabolism and
reactive oxygen species (ROS) [3].
In the pathogenesis of DOXO-induced myocardial dysfunction, the
contribution of eNOS-dependent oxidative stress has been reported
[4]. DOXO affects all NOS isoforms, causing the suppression of NOS
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activity, decreasing NO production and increasing superoxide anion
generation [4]. Cardioprotective effects of NO against DOXO-induced
cardiomyopathy have been previously reported [5]. In vivo long-term
dietary nitrate supplementation in mice not only improved the left
ventricular (LV) contractile and haemodynamic function, but also
reduced the susceptibility to DOXO-induced cell death [5]. These find-
ings implicate the importance of NO regulation as a key mediator in
DOXO-induced cardiomyopathy.
Several cofactors are required for NO generation, including
tetrahydrobiopterin, oxygen and NADH. Reduced bioavailability of
these factors could lead to NOS uncoupling and generate ROS instead
of NO [6]. FA, a member of the B-vitamin family, can enhance NO
generation in several ways, such as interacting directly or indirectly
with eNOS [7]. To this extent, a high dose of FA prevented ischaemia-
induced cardiac dysfunction and reduced reperfusion-induced cardiac
injury via eNOS recoupling [8].
In light of these considerations, we tested the hypothesis that FA
effectively reduces DOXO-induced cardiomyopathy in a mouse model
of acute DOXO administration by modulating eNOS and preserving
mitochondrial structure and function. In addition, we performed gen-
ome-wide expression profiling to further identify potential factors
implicated in DOXO-induced cardiomyopathy.
Materials and methods
Cytotoxicity assay
HeLa and MDA-MB-231 cells (ATCC, Teddington, Middlesex, UK), a
human cervical epithelial adenocarcinoma cell line and a human breast
adenocarcinoma cell line, respectively, were maintained in Dulbecco’s
Modified Eagle Medium (ThermoFisher, Waltham, MA, USA) supple-
mented with 10% foetal bovine serum (ThermoFisher, Waltham, MA,
USA) and 100U/ml penicillin-streptomycin (ThermoFisher, Waltham, MA,
USA). DOXO was added in a range of concentrations (10 lM to 0.1 nM)
with/without FA ranging from 10 lM to 1 nM (supra- and physiological
concentrations). Following this, the sulforhodamine B assay was per-
formed, and the OD values were read at 24, 48 and 72 hrs.
Experimental animals
Experiments were approved by the Institutional Animal Care and Use
Committee and were carried out in accordance with the EU Directive
2010/63/EU for animal experiments. C57BL/6 mice (265 total, male, 9–
11 weeks old; Charles River) were injected intraperitoneally with a sin-
gle dose of DOXO hydrochloride (20 mg/kg; Pfizer, New York, NY, USA)
as performed previously [9, 10]. Soft-dough diet (Transgenic Dough
Diet; Bio-Serv, Flemington, NJ, USA) with/without FA (10 mg/day;
Sigma-Aldrich, St.louis, MO, USA) was administered from 7 days before
the DOXO injection until the end of the experiment (10 days).
Echocardiographic measurements
Cardiac function and geometry were assessed by transthoracic echocar-
diography (Vevo 770) in anaesthetized mice (2.5% isoflurane) with body
temperature maintained at 37°C, at baseline (before DOXO injection)
and at 9 days post-injection. LV internal dimensions at end-diastole
(LVIDd) and end-systole (LVIDs), and LV posterior wall (LVPW) were
measured from M-mode images.
Histological and ultrastructural examination of
the heart
To assess myocyte width and fibrosis, hearts were fixed in 10% forma-
lin, embedded in paraffin, cut in 5 lm sections and stained with haema-
toxylin–eosin (HE) and picrosirius red (PSR) using standard protocols
as described previously [11]. Cardiac cell death was detected with the
TUNEL In Situ Cell Death Detection Kit (Roche Diagnostics, Almere, FL,
The Netherlands) as previously described [12]. In each group, 6–9 mice
with 3–4 heart sections for each mouse were stained and analysed.
For electron microscopy, LV samples were fixed in 3% glutaralde-
hyde, 1.4% sucrose in 0.09 M potassium dihydrogen phosphate buffer
(pH 7.4), post-fixed in 1% osmium tetroxide in 0.1 M phosphate buffer
(pH 7.4), dehydrated in graded ethanol series and embedded in Araldite.
Ultrathin sections (40–60 nm) were stained with uranyl acetate and lead
citrate. Photomicrographs were captured using a Philips CM100 trans-
mission electron microscope (Philips 201).
Mitochondrial function
Mitochondrial oxygen consumption was determined using a Clark electrode
in a continuously stirred and sealed respiration chamber as previously
described [13]. Briefly, the hearts were excised, and skinned fibre prepara-
tions of the LV were used. Following the measurement of basal function,
maximal ADP-stimulated respiration was determined by exposing fibres to
2 mM ADP using glutamate (5 mM) and malate (2 mM) as substrates [13].
Detection of superoxide anion
Superoxide anion generation was measured by two independent methods.
Homogenized LV was evaluated by low concentration lucigenin-enhanced
chemiluminescence (5 lmol/l) using a single-tube luminometer (Berthold
FB12). As a measure of NOS-derived superoxide anion generation, we
evaluated the difference in superoxide anion generation after 20 min.
incubation with NG- nitro-L-arginine methyl ester (L-NAME: 100 lmol/l)
and presented as DL-NAME. Superoxide anion generation was also mea-
sured by dihydroethidium (DHE) staining of LV tissue sections.
Protein measurements
Protein levels were determined in homogenates of myocardial samples as
previously described [14]. Primary antibodies were phospho-eNOS
S1177, eNOS, nNOS, iNOS, GAPDH (Cell Signaling, Danvers, MA, USA;
BD Transduction Laboratories, Heidelberg, Germany; Santa Cruz, Abing-
don, UK; Imgenex, Cambridge, UK) and used at 1:1000.
Monomer:dimer ratio was determined using cold SDS-PAGE Western
blot in 4%–7% SDS-Tris gels at 4°C. Subsequently, the proteins were
transferred to nitrocellulose membranes and were probed with primary
and secondary antibodies (LI-COR). All blots were analysed using the
Odyssey system.
2 ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
S-glutathionylation of eNOS was determined by co-immunoprecipita-
tion of LV homogenates. Briefly, protein G (Invitrogen)-conjugated
anti-eNOS (Santa Cruz) was incubated overnight with LV homogenates
at 4°C. After washing with PBS, eNOS was immunoblotted with
anti-GSH (Virogen, Watertown, MA, USA) in the presence or absence
of DTT (10 lmol/l) to remove the glutathionylation modification of
eNOS.
Myocardial NO production
Myocardial NO production was evaluated as the measurement of
nitrate + nitrite using the Griess reaction colorimetric assay (Cayman
CHemical, Ann Arbor, MI, USA) per manufacturer’s instructions.
Antioxidant activity
Total superoxide dismutase (SOD) activity and the GSSG (oxidized glu-
tathione)-to-GSH (reduced glutathione) ratio were assessed with com-
mercially available kits (Cayman Chemical, Ann Arbor, MI, USA) per
manufacturer’s instructions.
Hybridization and microarray profiling
Total RNA was isolated using the RNeasy Fibrous Tissue Mini kit (Qia-
gen, Venlo, NB, The Netherlands) per manufacturer’s instructions. RNA
quality and quantity were established using a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). Biotinylated complementary RNA
was prepared and hybridized to the Mouse Gene 1.0 ST array (Affyme-
trix, Waltham, MA, USA) according to the Affymetrix processing proto-
col. The array was scanned in a GeneChip Scanner 3000. The quality
of hybridization was assessed in all samples following manufacturer’s
recommendations. Microarray data are deposited in the Gene Expres-
sion Omnibus database (accession No. GSE64476). The computational
and statistical analysis of the microarray data was carried out using
the R version 2.14.2 software (https://www.r-project.org/) and the Bio-
conductor packages (https://www.bioconductor.org/) as performed pre-
viously [11, 15–17]. Gene lists were generated selecting for candidates
with an uncorrected P value threshold of 0.01 as performed recently
[15].
Quantitative real-time RT-PCR
Quantitative analysis was performed by real-time PCR with specific
primers and SensiMixTM SYBR & Fluorescein Kit using iQ5 (Bio-Rad, Vee-
nendaal, UT, The Netherlands). Primer sequences are shown in Table S1.
Statistical analysis
Data are presented as mean  S.E.M. Analysis of survival rates was
performed with the log-rank test. All data were tested using two-way
ANOVA with Student-Newman-Keuls post hoc test considering P < 0.05
significant.
Results
FA did not interfere with DOXO cell-killing
capacity
To investigate whether treatment with FA reduces the main tumour
cell-killing effects of DOXO, we employed the human cervical epithe-
lial adenocarcinoma HeLa cell line and the human breast adenocarci-
noma MDA-MB-231 cell line treating them with different doses of
DOXO and FA. DOXO in the absence or presence of FA at various con-
centrations exerted similar cytotoxic effects in HeLa and MDA-MB-
231 cancer cells (Fig. S1). Therefore, the antitumour activity of DOXO
was not affected by FA.
FA blunted DOXO-induced mortality
DOXO resulted in 70% mortality 10 days after injection, which was
decreased to 45% by pre-treatment with FA (Fig. 1). At baseline, body
weights were similar in all groups. DOXO produced a significant loss
of body weight versus the corresponding sham group, which was not
significantly affected by FA (Table S2).
FA normalized DOXO-induced left ventricular
structural and functional changes
DOXO led to significant reductions in LVIDd and LVIDs, LV
weight and LV lumen (Fig. 2A–D). These DOXO-induced structural
changes had the functional consequence of decreased stroke vol-
ume versus the corresponding sham group (Fig. 2E). Importantly,
pre-treatment with FA attenuated all these deleterious changes
(Fig. 2A–E). Heart rate was not significantly affected in any group
(Fig. 2F).
Fig. 1 Effects on mortality. DOXO, doxorubicin; FA, folic acid. *P<0.01
versus corresponding Sham; †P<0.01 DOXOFA versus DOXO.
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FA attenuated DOXO-induced cardiomyocyte
atrophy, cardiac apoptosis and fibrosis
Investigating the underlying cellular mechanisms, we found that the
LV myocardium of mice receiving DOXO alone displayed a reduction
in cardiomyocyte width and increases in collagen content and apopto-
sis (Fig. 3A–D). FA exerted significant protective effects against these
DOXO-induced deleterious effects (Fig. 3A–D).
FA prevented DOXO-dependent impairment of
mitochondrial function and ultrastructure
DOXO has been shown to inhibit complex I of the electron transport
chain and concomitantly induces mitochondrial dysfunction, while
nitrate supplementation has been shown to protect mitochondrial
oxygen respiration [5]. Therefore, we hypothesized that FA, as NOS
modulator, might exert further protective effects against mitochon-
drial dysfunction. As in our preliminary measurements we did not find
any significant differences between the sham and FA-sham groups,
we merged the two groups into a single one to lower the number of
animals used. We found that while ADP-stimulated mitochondrial res-
piration (state 3) was diminished in the DOXO group, it was main-
tained in mice pre-treated with FA (Fig. 4A).
Ultrastructural analysis of the sham group showed normal mito-
chondrial structure with preserved internal architecture and surround-
ing organized myofibrils (Fig. 4B). Samples of DOXO mice
demonstrated prominent patchy myofibrillar loss and disarray. More-
over, mitochondria showed significant abnormalities, such as
enlargement, contour irregularities, increased spacing between cris-
tae and disruption of the internal architecture. Pre-treatment with FA
markedly prevented DOXO-induced mitochondrial ultrastructural
degeneration (Fig. 4B).
FA blunted DOXO-induced oxidative stress, eNOS
and antioxidant dysregulation
To unravel the molecular underpinnings of the FA-mediated protec-
tion against the deleterious effects of DOXO, we studied the effects of
FA on DOXO-induced oxidative stress. Indeed, superoxide anion pro-
duction was significantly increased in LV homogenates from DOXO
Fig. 2 Effects on cardiac function and structure. Left ventricular (LV) internal diameter at end-diastole (LVIDd), (A) and end-systole (LVIDs), (B) nor-
malized to tibia length (TL). (C) LV weight/TL. (D) LV lumen. (E) Stroke volume. (F) Heart rate. The n is indicated directly in the graph bars in all
figures. BPM, beats per min. *P < 0.01 versus corresponding Sham; §P < 0.05 versus corresponding Sham; †P < 0.01 FA-DOXO versus DOXO;
‡P < 0.05 FA-DOXO versus DOXO.
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mice versus sham mice, which appeared to be largely NOS-depen-
dent, as it was markedly attenuated by the NOS inhibitor L-NAME
(Fig. 5A-D). DOXO did not lead to changes in nNOS and iNOS levels
or the respective monomer:dimer ratios (Fig. S2). However, DOXO
increased the eNOS monomer:dimer ratio, indicative of eNOS uncou-
pling, and decreased eNOS phosphorylation at S1177, indicative of
reduced eNOS activity (Fig. 5E and F).
S-glutathionylation of eNOS has been recently found as the trigger
of eNOS uncoupling [18]. Therefore, we assessed the levels of eNOS
S-glutathionylation and found a significant increase related to DOXO
versus sham (Fig. 5G). S-glutathionylation occurs due to elevation of
glutathione disulphide (GSSG, oxidized glutathione) [18]. The ratio
GSSG to glutathione (GSH, reduced glutathione) was increased in
DOXO versus sham group (Fig. 5H). In parallel, more than 50% super-
oxide dismutase (SOD) activity was decreased (Fig. 5I). DOXO reduced
myocardial NO production by 50% versus sham mice (Fig. 5J).
Notably, pre-treatment with FA restored eNOS and antioxidant
enzymes dysregulation, which were associated with an increase in NO
production and a decrease in NOS-dependent superoxide anion for-
mation (Fig. 5A–J).
FA modulated DOXO-induced transcriptomic
changes
To further investigate the molecular mechanisms of FA-mediated pro-
tection against DOXO-induced cardiomyopathy, we performed gen-
ome-wide expression profiling of LV samples. To extract biologically
useful information, we examined those genes with an unadjusted
P < 0.01 as performed previously [15]. Our analysis revealed that
152 transcript clusters were regulated by DOXO alone versus the
sham group (Table S3), while 68 transcript clusters were differentially
Fig. 3 Effects on cardiomyocyte width, cardiac fibrosis and apoptosis. (A) Myocyte width evaluation using haematoxylin–eosin (HE) staining. (B) Colla-
gen content measurements using picrosirius red (PSR) staining. (C) Cardiomyocyte apoptosis as assessed by TUNEL positive nuclei. (D) Representa-
tive images of stained sections. *P < 0.01 versus corresponding Sham; §P < 0.05 versus corresponding Sham; †P < 0.01 FA-DOXO versus DOXO.
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regulated between the FA-DOXO and DOXO groups (Table S4). Inter-
estingly, 71 transcript clusters were found significant by the interac-
tion analysis (Table S5). Among the most up-regulated genes by
DOXO, we identified a ca. 10-fold increase in metallothionein-2 (Mt2),
a gene that is involved in oxidative stress, and apoptotic factor lipoca-
lin-2 (Lcn2) with a ca. fivefold increase compared with controls. Fur-
thermore, we found that the desmosomal gene Adam4 was repressed
in DOXO-treated mice by ca. 30%, while its expression was restored
in FA-DOXO-treated mice. Also, several members of the cysteine pro-
tease inhibitors (stefins) were induced in DOXO-treated mice versus
controls, while their expression was normalized by FA.
To validate genes involved in DOXO-induced cardiomyopathy and
modulated by FA, we performed quantitative real-time RT-PCR analy-
sis selecting several candidates that exhibited significant induction.
Similar to the microarray data analysis, we found that DOXO induced
the expression of Mt2, Lcn2, and Serpina3n, which was decreased by
FA (Fig. 6A–C). We further analysed the expression of foetal genes
and found a decrease in Acta1 and an increase in Nppa and Nppb
expression in the DOXO group, which was normalized in the FA-DOXO
group (Fig. 6D–F).
Discussion
In a mouse model of DOXO-induced cardiomyopathy, we report for
the first time that pre-treatment with FA, an eNOS modulator, attenu-
ated DOXO-induced mortality and markedly reduced LV structural
damage. Oral supplementation of FA attenuated cardiomyocyte atro-
phy, cardiac apoptosis and fibrosis, maintained mitochondrial integ-
rity and reduced superoxide anion production. Mechanistically, our
data suggest that these cardioprotective effects of FA may be medi-
ated via eNOS recoupling, with enhanced phosphorylation of eNOS at
S1177 and reduced glutathionylation of eNOS, both of which result in
improved cardiac NO production.
Anthracycline-induced cardiomyopathy remains a significant
problem in both oncology and cardiology practices [2]. Our hypoth-
esis to test a pharmacological intervention with FA against DOXO-
induced cardiomyopathy was based on the ability of FA to improve
outcome in primary prevention of cardiovascular disease [7, 8].
Our data demonstrate that treatment with FA significantly reduced
DOXO-induced mortality. This raised the question whether FA could
actually interfere with and attenuate the antitumour capacity of
DOXO. Our in vitro data showed that co-administration of DOXO
and FA to the tumour cell lines HeLa and MDA-MB-231 did not
interfere with DOXO main effects, as DOXO was still able to exert
its antitumour actions.
The effects of DOXO on LV remodelling and dysfunction are still
incompletely understood, as several studies in rodents have demon-
strated contradictory results depending on the dose and duration fol-
lowing DOXO administration. Consequently, DOXO has been reported
to elicit inward remodelling [9, 19], outward remodelling [20, 21] or
no effects on cardiac remodelling [22, 23], irrespective of the
observed reductions in stroke volume [19, 23, 24] and cardiac output
[25]. In our model, DOXO induced inward LV remodelling, as indi-
cated by the reduced cardiac dimensions resulting in decreased
stroke volume. However, the pre-treatment with FA led to a significant
reduction in DOXO-induced cardiomyopathy, and cardiac morphome-
try and function were normalized back to sham levels.
Fig. 4 Effects on mitochondrial function and ultrastructure. (A) Mito-
chondrial oxygen consumption as measured by state 3. (B) Representa-
tive transmission electron microscopy images. *P < 0.01 versus Sham;
‡P < 0.05 versus DOXO.
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Consistent with previous observations [20, 21], we observed that
interstitial fibrosis and apoptosis are prominent features of DOXO-
induced cardiomyopathy and likely contributed to the effects of DOXO
on LV dysfunction. FA not only attenuated these pathological
changes, but also reduced DOXO-induced cardiomyocyte atrophy,
thereby blunting the loss of LV mass.
Furthermore, it was demonstrated that DOXO results in desmin dis-
ruption and myofibrillar disorganization [26]. As desmin adheres to
mitochondria, desmin disarray might be related with mitochondrial
dysfunction. Along this line, previous studies have suggested the
involvement of mitochondria in DOXO-induced cardiomyopathy [5,
26]. In the present study, we confirmed DOXO-induced mitochondrial
Fig. 5 Effects on oxidative stress, endothelial nitric oxide synthase (eNOS) modulation and antioxidant system. (A) Using lucigenin-enhanced chemi-
luminescence, superoxide anion production is expressed as the relative light unit (RLU) per second per gram of protein. (B) Substraction of luci-
genin-enhanced chemiluminescence with NG- nitro-L-arginine methyl ester (L-NAME) incubation from total superoxide anion, presented as D L-
NAME. (C) Dihydroethidium (DHE) fluorescence quantification from LV sections. (D) Representative DHE-stained sections. (E) Monomer:dimer ratio
of eNOS. (F) Phosphorylation of eNOS at serine 1177. (G) S-glutathionylation of eNOS. The representative co-immunoprecipitation of eNOS without
(top) and with (bottom) DTT to remove glutathionylation. Unspecific mouse IgG antibody was used as a negative control. (H) Ratio between oxidized
glutathion (GSSG) and reduced glutathion (GSH). (I) Superoxide dismutase (SOD) activity. (J) Cardiac NO production analysed by total nitrate and
nitrite. *P < 0.01 versus corresponding Sham; §P < 0.05 versus corresponding Sham; †P < 0.01 FA-DOXO versus DOXO.
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
7
J. Cell. Mol. Med. Vol XX, No X, 2017
dysfunction, as indicated by impaired mitochondrial function and major
mitochondrial morphological changes. Notably, FA was able to normal-
ize mitochondrial function and to maintain mitochondrial integrity.
FA regulates intracellular eNOS signalling via indirect or direct
mechanisms, including eNOS phosphorylation at multiple residues
[7], leading to NO release and restoring the balance between NO and
superoxide anion production, which is associated with cardioprotec-
tion. However, the role of eNOS in DOXO-induced cardiomyopathy
remains incompletely understood. It was reported that DOXO gener-
ates superoxide anion, which was decreased in eNOS KO mice and
increased in mice with overexpression of eNOS [27]. These results
suggested that DOXO induces superoxide anion via an eNOS-depen-
dent mechanism, and removal of dysfunctional eNOS is beneficial
against DOXO-induced cardiomyopathy. However, the authors did not
find eNOS uncoupling at day 5 in WT mice, while we found eNOS
uncoupling at day 10. Importantly, we found that pre-treatment with
FA prevented eNOS uncoupling and normalized the phosphorylation
of eNOS at S1177, resulting in decreased superoxide anion generation
and restored myocardial NO production, thereby leading to an adap-
tive response preserving cardiac function, ultimately providing cardio-
protection and improving mortality. Therefore, it would be very
informative to obtain data on eNOS uncoupling on a later time-point
Fig. 6 Effects on transcriptomic regulation. Messenger RNA levels of Mt2 (A), Lcn2 (B), Serpina3n (C), Acta1(D), Nppa (E), Nppb (F) normalized to Gapdh.
*P < 0.01 versus corresponding Sham; §P < 0.05 versus corresponding Sham; †P < 0.01 FA-DOXO versus DOXO; ‡P < 0.05 FA-DOXO versus DOXO.
Fig. 7 Schematic presentation of the prevention of DOXO-induced cardiomyopathy and mortality by FA.
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or in mice overexpressing eNOS, which could be compared with the
data presented here.
We also found a significantly decreased total LV SOD activity in
DOXO mice, which was blunted by pre-treatment with FA. In addition,
S-glutathionylation of eNOS, which can be a direct result of elevated
GSSG levels or an indirect result of the formation of unstable protein
radicals, may adversely modulate eNOS structure and function and
generate superoxide anion [18]. Thus, it is important to understand
the effect of this oxidative modification and modulate S-glutathionyla-
tion. Interestingly, we found that DOXO increased the GSSG:GSH
ratio, leading to S-glutathionylation of eNOS, and that this was
blunted by pre-treatment with FA.
There are other mechanisms by which DOXO can lead to altered
cardiac metabolism and induce superoxide anion generation [3].
These include DOXO-induced ROS generation through topoiso-
merase II-dependent DNA double-strand breaks, which lead to apop-
tosis and mitochondrial damage [28]. Recently, a novel mechanism
on the involvement of late sodium current (INa) in the modulation of
cardiac redox balance in DOXO-induced cardiomyopathy was
reported [29]. Interestingly, it was shown that ranolazine, an INa inhi-
bitor, protects against DOXO-induced cardiac dysfunction and
remodelling [29]. Furthermore, both DOXO and FA have been shown
to produce alterations in DNA methylation status in the heart [30,
31]. On the basis of these observations, it is possible that other
effects of FA may have also contributed to the protection against
DOXO-induced toxicity.
The molecular signalling pathways linking ROS with gene modi-
fications involved in pathophysiological remodelling of the heart are
not fully understood. Therefore, we performed comparative tran-
scriptomic analysis, which revealed marked DOXO-induced up-regu-
lation of Nppa and Nppb, which are markers of cardiac
dysfunction, and down-regulation of the desmosomal gene Adam4
and the cysteine protease inhibitors stefins. Desmosomes are cru-
cial for tissue homoeostasis and cardiac integrity [32]. The cysteine
protease inhibitors stefins have been proposed as prognostic and
diagnostic tools for cancer and may have an important role in
desmosome-mediated cell–cell adhesion [33]. The role of this regu-
latory family in the heart is unknown and warrants further investi-
gation. Although in the present study we did not measure protein
abundance or activity, we put forward that these may be additional
mechanisms involved in the protective effects of FA against DOXO-
induced cardiomyopathy.
Our study was limited to a single dose of acute DOXO administra-
tion in mice in the absence of cancer, while in patients DOXO is
chronically administered. However, this is an established model of
DOXO-induced cardiomyopathy that shares features with the car-
diomyopathy observed in patients following chronic administration of
DOXO [9, 10, 27], and our in vitro data showed that co-administration
of FA did not affect the tumour cell-killing capacity of DOXO. Never-
theless, further experiments are necessary to investigate the effects
of FA in a chronic model of DOXO administration, which may reflect
the clinical situation more closely. Moreover, in our study, mortality
reached 70% after 10 days of DOXO administration, which might be
considered relatively high. However, 50% mortality was previously
reported after 8 days of DOXO administration [27], at which point we
observed 60% mortality, and even 90% mortality after 10 days of
DOXO administration has been reported [10]. It has to be noted,
however, that this might be a strain-specific effect, as ca. 21% mor-
tality was reported after 9 days of DOXO administration in CF-1 out-
bred mice [34]. Furthermore, we limited ourselves to a single dose of
FA, which does not exclude varying effects at different doses. Never-
theless, our study indicates that FA decreased acute DOXO-induced
cardiomyopathy and mortality even at supratherapeutic levels of
DOXO. Considering the sex differences in DOXO cardiotoxicity
recently reported [35], it would also be interesting to assess whether
the efficacy of FA to attenuate DOXO-induced cardiomyopathy might
differ between the sexes.
In conclusion, the development of therapeutic strategies targeting
eNOS via FA supplementation may prove a major step forward in
addressing DOXO-induced cardiomyopathy. Considering its robust
safety profile and its widespread use as dietary supplement, FA may
hold promise for oncologists and haematologists to prevent DOXO-
induced cardiomyopathy and mortality (Fig. 7).
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